The mammalian myocardium expresses four adenosine receptor (AR) subtypes: A1AR, A2aAR, A2bAR, and A3AR. The A1AR is well known for its profound antiadrenergic effects, but the roles of other AR subtypes in modulating contractility remain inconclusive. Thus, the objective of this study was to determine the direct and indirect effects of A2aAR and A 2b AR on cardiac contractility. Experiments were conducted in paced, constant pressure-perfused isolated hearts from wild-type (WT), A2aAR knockout (KO), and A 2b AR KO mice. The A2aAR agonist CGS-21680 did not alter basal contractility or ␤-adrenergic receptor agonist isoproterenol (Iso)-mediated positive inotropic responses, and Iso-induced effects were unaltered in A2aAR KO hearts. However, A2aAR gene ablation resulted in a potentiation of the antiadrenergic effects mediated by the A1AR agonist 2-chloro-N-cyclopentyladenosine. The nonselective AR agonist 5=-N-ethylcarboxamido adenosine and the selective A2bAR agonist BAY 60-6583 induced coronary flow-independent increases in contractility, but BAY 60-6583 did not alter Iso-induced contractile responses. The A1AR antiadrenergic effect was not potentiated in A2bAR KO hearts. The expression of all four AR subtypes in the heart and ventricular myocytes was confirmed using real-time quantitative PCR. Taken together, these results indicate that A2aAR does not increase cardiac contractility directly but indirectly alters contractility by modulating the A1AR antiadrenergic effect, whereas A2bAR exerts direct contractile effects but does not alter ␤-adrenergic or A1AR antiadrenergic effects. These results indicate that multiple ARs differentially modulate cardiac function.
the positive inotropic effects of ␤-adrenergic stimulation at the whole heart and myocyte levels (7, 12) . There is evidence for the presence of A 2a AR on ventricular myocytes, but there are contradictory reports on the ability of this receptor to alter cardiac contractility. Previous work from our laboratory (13) has provided immunological evidence for the expression of A 2a AR in rat ventricular myocytes, although the A 2a AR-selective agonist CGS-21680 exerted no effects on myocyte shortening or cAMP. Additional studies from our laboratory (14, 16) have indicated that A 2a AR stimulation has no effects on contractility in isolated rat hearts and intact porcine myocardium. Our findings are consistent with those of a study by Headrick et al. (31) in which it was also shown that A 2a AR activation has no contractile effects in isolated mouse hearts. In contrast, other reports (6, 8, 20, 30, 33) have indicated that A 2a AR stimulation increases contractility in isolated rat and mouse hearts and in isolated rat cardiomyocytes.
In addition to inconsistencies in the observed direct effects of A 2a AR on contractility, there are also discrepancies regarding the indirect effects of A 2a AR activation. It has been reported that the A 2a AR agonist CGS-21680 potentiates the positive inotropic effects of ␤-adrenergic receptor stimulation in the mouse heart (30) but not in rat ventricular myocytes (8) . In addition, it has been observed that the AR antagonist ZM-241385, which exhibits some selectivity toward A 2a AR, potentiates A 1 AR antiadrenergic effects in isolated perfused rat hearts and myocytes (8, 23) . However, when the hypothesis that A 2a AR antagonizes the A 1 AR antiadrenergic effect was tested using AR knockout (KO) mice, it was observed that the A 1 AR antiadrenergic effect was reduced in A 2a AR KO mice (30) . The basis for such inconsistencies regarding A 2a ARmediated direct and indirect contractile effects remains unclear.
A 2b AR, which exhibits a low affinity for adenosine, is the least well-characterized AR in the mammalian heart. Although it has been shown to be expressed in several cell types in the myocardium (4, 11, 25, 27, 28) , its expression in mammalian ventricular myocytes has yet to be confirmed. The contractile effects of A 2b AR have not been studied in detail, due to the lack of readily available selective agonists and antagonists. One study (31) using wild-type (WT) mice reported that A 2b AR may be responsible for a small, but sustained, positive inotropic effect after adenosine administration in isolated perfused mouse hearts. In the only study (28) conducted thus far with a selective A 2b AR-selective agonist, BAY 60-6583 exerted dose-dependent increases in ventricular function in parallel with coronary vasodilation. Thus, similar to A 2a AR, the effects of A 2b AR stimulation on cardiac contractility remain inconclusive.
Given these inconsistencies, the objectives of this study were to examine the direct effects of A 2a AR and A 2b AR on cardiac contractility as well as A 2a AR and A 2b AR modulation of ␤-adrenergic contractile responses. Furthermore, real-time quantitative PCR was used to assess the expression of all four AR subtypes in whole ventricles and isolated ventricular myocytes.
MATERIALS AND METHODS
Materials. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. The A 2bAR agonist BAY 60-6583 was a kind gift from Dr. Thomas Krahn at Bayer Healthcare (Wuppertal, Germany). 2-chloro-N-cyclopentyladenosine (CCPA), CGS-21680, 5=-N-ethylcarboxamido adenosine (NECA), and BAY 60-6583 were prepared as 10 mM stock in DMSO and diluted as necessary. Isoproterenol (Iso) was prepared as a 10 mM stock solution in PBS with 0.1% sodium metabisulfite.
Animals. The animals in this study were maintained and used in accordance with guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and were evaluated and approved by the Institutional Animal Care and Use Committee of Wayne State University. Ten-to twelve-week-old male C57BL/6 (WT) mice were purchased from Jackson Laboratories (Bar Harbor, ME). The progenitors for A 2aAR and A2bAR constitutive global homozygous KO (Ϫ/Ϫ) mice were generous gifts from Dr. Joel Linden (La Jolla Institute for Allergy and Immunology, La Jolla, CA) and Dr. Stephen Tilley (University of North Carolina, Chapel Hill, NC), respectively. The genotype of the offspring was validated by PCR (using tail genomic DNA) or RT-PCR (using mRNA isolated from hearts after some experiments). In a subset of isolated hearts, the respective genotypes were also verified by lack of responsiveness to the A 2aAR agonist CGS-21680 and the A2bAR agonist BAY 60-6583.
Isolated heart preparation (general protocol). Hearts were excised from anesthetized (60 mg/kg pentobarbital sodium) and heparinized (500 units) mice, placed in cold (4°C) saline, and mounted on the perfusion apparatus. Hearts were perfused at constant coronary perfusion pressure (70 mmHg) with standard Krebs-Henseleit buffer (KHB). Heart temperature was maintained at 37°C with constanttemperature reservoirs and by partially submerging the heart into a water-jacketed chamber filled with KHB. Hearts were paced at 420 beats/min via pacing wires inserted into the right ventricle, and a fluid-filled balloon was inserted into the left ventricle (LV) across the mitral valve and connected to a pressure transducer, permitting continuous measurements of LV pressure and heart rate (HR). Ventricular function [LV systolic pressure (LVSP), ϩdP/dt, and ϪdP/dt], HR, coronary flow (CF), and perfusion pressure were continuously monitored and recorded throughout the experiments. All data collected were analyzed with PowerLab and Chart Software for Windows (AD Instruments, Colorado Springs, CO).
Experimental protocols. Hearts were allowed to equilibrate for ϳ20 min before any experimental protocols. Dose-response curves were generated by exposing the hearts to increasing concentrations of agents (100, 500, and 1,000 nM), and steady-state responses were recorded. To determine the effects of AR agonists on ␤-adrenergic responses, hearts were pretreated with CCPA, CGS-21680, or BAY 60-6583 (all at 200 nM) for 5 min before and during Iso exposure. Steady-state responses to Iso (2 and 10 nM) were assessed after 2 min. Only a single experimental protocol was conducted in each heart.
CCPA and CGS-21680 exhibit selectivity for human and rat A 1AR and A2aAR, respectively, whereas NECA is nonselective and activates A2bAR at high nanomolar concentrations (34) . BAY 60-6583 is a new agonist that has been reported to have a Ki of 0.33 M for mouse A2bAR (1) . It has also been reported that this agonist exerts no effects on cAMP in Chinese hamster ovary cells transfected with human A1AR and A2aAR (10) .
Myocyte isolation protocol. Adult mouse ventricular myocytes were isolated from hearts of WT and A2aAR KO hearts using standard retrograde perfusion/enzymatic dissociation methods, as previously described (24) . After isolation and Ca 2ϩ restoration to 1 M, myocytes were preplated on 10-cm tissue culture-treated dishes for 2 h at 37°C to remove fibroblasts and other nonmyocytes, which adhere to plastic. The unattached cell supernatant was then gravity settled through a 5% BSA solution to further enrich the pellet in cardiomyocytes. The supernatant was discarded, and the resulting pellet was used for RNA isolation.
RNA isolation and real-time quantitative PCR. Total RNA was isolated from WT and A 2aAR KO mouse ventricular tissue and isolated ventricular myocytes using TRIzol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). RNA was digested with DNase I and purified using a RNeasy Mini Kit (QIAGEN, Valencia, CA), and RNA quality and quantity were validated by spectrophotometry and agarose gel electrophoresis. All reagents necessary for real-time PCR were purchased from Applied Biosystems (Carlsbad, CA). Reverse transcription was performed on 1 g total RNA using the High-Capacity cDNA reverse transcription kit. Gene expression was assayed with TaqMan Universal PCR Master Mix and FAM-labeled TaqMan inventoried gene expression assays according to the manufacturer's instructions. Real-time PCR was conducted in a StepOnePlus Real-Time PCR System, and data were analyzed by the comparative 2
Ϫ⌬Ct method (where Ct is threshold cycle) and expressed as a percentage of the internal endogenous control gene GAPDH.
Data and statistical analysis. Data were analyzed with GraphPad Prism software and are presented as means Ϯ SE. Functional data were analyzed using one-or two-way ANOVA where appropriate. Statistically significant differences between gene expression in the heart and myocyte preparations were calculated by an unpaired t-test. Statistically significant differences in the values were taken at P Ͻ 0.05.
RESULTS
Baseline cardiac contractile parameters and CF from WT, A 2a AR KO, and A 2b AR KO mice are shown in Table 1 . There were no differences in baseline hemodynamics among the groups. There were also no differences in body weights or heart weight-to-body weight ratios.
A 2a AR effects on cardiac contractility. The contractile effects of A 2a AR activation were evaluated in WT mouse hearts using the A 2a AR-selective agonist CGS-21680. As shown in Table 2 the A 2a AR-selective agonist CGS-21680 increased CF by 50%, but this was associated with no significant effects on contractility even at the highest concentration tested (1 M). As shown in Table 2 , administration of Iso resulted in dosedependent increases in all contractile parameters and CF. Pretreatment with CGS-21680 (200 nM) before and during Iso stimulation did not alter ␤-adrenergic contractile responses at either Iso concentration.
The ability of A 2a AR to indirectly alter myocardial contractility (i.e., by modulating the A 1 AR-mediated antiadrenergic response) was investigated using WT and A 2a AR KO mice. As shown in Fig. 1 , the ␤-adrenergic agonist Iso increased LVSP, ϩdP/dt, and ϪdP/dt by 76%, 109%, and 133%, respectively, at a concentration of 2 nM Iso and by 107%, 190%, and 204%, respectively, at 10 nM Iso. Pretreatment of additional hearts with the A 1 AR agonist CCPA exerted a potent antiadrenergic effect where contractility was attenuated significantly (at 2 nM Iso, LVSP, ϩdP/dt, and ϪdP/dt were reduced by 54%, 56%, and 58%, respectively). The A 1 AR agonist also blunted the effects of 10 nM Iso, although the extent of inhibition was lower (27%, 29%, and 32% reductions of LVSP, ϩdP/dt, and ϪdP/dt, respectively).
Deletion of A 2a AR had no effect on Iso-mediated contractile responses (Fig. 1) ; however, the A 1 AR antiadrenergic effect was significantly potentiated in A 2a AR KO hearts compared with their WT counterparts. In A 2a AR KO hearts, CCPA reduced the effects of 2 nM Iso by 81%, 86%, and 80% for LVSP, ϩdP/dt, and ϪdP/dt, respectively. Compared with WT controls, these values represent a further reduction in contractility by 58%, 68%, and 52% for LVSP, ϩdP/dt, and ϪdP/dt, respectively (Fig. 1) . The potentiation of the A 1 AR antiadrenergic effect in A 2a AR KO hearts was more pronounced at the lower Iso concentration, as the only significant difference between WT and A 2a AR KO hearts at 10 nM Iso was on ϩdP/dt (with a further reduction of 35% in A 2a AR KO hearts; Fig. 1B) .
A 2b AR effects on cardiac contractility. The effects of A 2b AR activation were evaluated in WT hearts using the nonselective agonist NECA and the A 2b AR-selective agonist BAY 60-6583. In contrast to the A 2a AR agonist, both NECA ( Fig. 2A) and BAY 60-6583 (Fig. 3A) increased contractility. NECA exerted statistically significant effects on all three contractile parameters at a concentration of 1 M, with LVSP, ϩdP/dt, and ϪdP/dt increasing by 11%, 15%, and 22%. Although NECA increased CF by ϳ60% (Fig. 2B) , there was a dissociation of the contractile and vasodilatory effects. CF was nearly maximal at 100 nM NECA, at a 10-fold lower dose than needed to increase contractility. In addition, the NECA-induced increase in contractile parameters abated within 10 min after agonist treatment was discontinued, but CF remained elevated. Similar effects were observed with the selective A 2b AR agonist BAY 60-6583. At concentrations of 500 nM and 1 M, BAY 60-6583 significantly increased contractility, with LVSP, ϩdP/ dt, and ϪdP/dt increasing by 13%, 18%, and 29% at the higher concentration (Fig. 3A) . The A 2b AR agonist increased CF by Ͼ50% at 100 nM, with little additional increase as the concentration was increased (Fig. 3B ). As seen with NECA, CF remained elevated after the discontinuation of BAY 60-6583 treatment, but contractility decreased to baseline levels. The results shown in Table 3 indicate that the hemodynamic effects of BAY 60-6583 were absent in A 2b AR KO hearts.
Additional experiments determined whether A 2b AR modulated the contractile effects of ␤-adrenergic stimulation or the A 1 AR antiadrenergic effect. As shown in Fig. 4A , the A 2b AR agonist (200 nM) did not alter the positive inotropic effects of Iso on LVSP. A similar trend was observed for ϩdP/dt and ϪdP/dt, where, in the presence of BAY 60-6583, contractility remained indistinguishable from that with Iso alone (data not shown). The results shown in Fig. 4B indicate that deletion of A 2b AR had no effect on Iso-induced increases in LVSP, nor did it alter the A 1 AR antiadrenergic effect. Similar patterns were observed for ϩdP/dt and ϪdP/dt (data not shown). These findings indicate that, unlike in A 2a AR KO hearts, there was no potentiation of the A 1 AR antiadrenergic effect in A 2b AR KO hearts.
Gene expression of ARs. Real-time quantitative PCR was used to assess the expression levels of the genes encoding all four AR subtypes in adult murine ventricular myocardium and isolated ventricular myocytes in WT and A 2a AR KO hearts. As shown in Fig. 5A , all four AR subtypes were expressed in the mouse ventricle, with A 1 AR and A 2a AR subtypes expressed to a much greater extent than A 2b AR and A 3 AR subtypes. Deletion of A 2a AR did not result in any significant changes in the expression of the other receptor subtypes. Figure 5B shows that the mRNA for all four subtypes was expressed in enriched myocyte preparations, albeit at lower levels than in intact hearts (with the exception of A 1 AR). The enrichment of the myocyte sample (ϳ80% cardiomyocytes) was based on the mRNA levels of troponin T compared with mRNA levels of the fibroblast marker discoidin domain receptor, type 2, vascular endothelial cadherin, and smooth muscle markers calponin and SM22. Myocytes isolated from A 2a AR KO hearts exhibited similar levels of receptor mRNA expression, although the A 2b AR message was greater than in WT myocytes. A 2a AR modulation of cardiac contractility. The present findings indicate that A 2a AR stimulation exerts potent coronary vasodilatory effects but no direct effects on cardiac contractility. CF increased by 50%, but cardiac function did not change with increasing concentrations of the A 2a AR agonist (up to 1 M). These results are consistent with our previous reports as well as those of others (13, 16, 19, 31) showing that A 2a AR stimulation does not alter cardiac function in isolated perfused rat hearts or isolated cardiac myocytes. In contrast, it has been reported that the A 2a AR agonist CGS-21680 (100 nM) increased LV developed pressure in isolated mouse hearts by ϳ80% (20) . However, this same concentration also increased CF by 500%, and the A 2a AR dose-response curves for LV function and coronary vasodilation exhibited similar EC 50 values. Willems and Headrick (31) concluded that this significant increase in contractility was due to the Gregg phenomenon or the garden hose effect (flow-induced increases in ventricular function). In the only other study to date in mouse myocardium, Tikh et al. (30) concluded that A 2a AR stimulation with CGS-21680 increased contractility by ϳ5-10%, but these authors did not present specific data to support this conclusion. There have been few in vivo studies in large or small animals due to the fact that the majority of A 2a AR agonists exert significant reductions in afterload, thus invalidating the use of standard measurements of cardiac function. We (14) have previously reported, however, that using loadinsensitive measurements of cardiac contractility [preload recruitable stroke work (PRSW) and PRSW area] in an intact porcine preparation that an intracoronary infusion of CGS-21680 increased regional coronary blood flow by 150% but exerted no effects on regional cardiac contractility.
The present findings also indicate that A 2a AR does not alter ␤-adrenergic receptor-mediated increases in cardiac contractility. In WT hearts, the A 2a AR agonist CGS-21680 (200 nM) did not alter Iso-mediated increases in LVSP, ϩdP/dt, or ϪdP/dt. In addition, contractile responses to Iso were not altered in A 2a AR KO hearts, indicating that gene ablation did not alter the normal ␤-adrenergic response. Results from a previous study (30) in isolated perfused mouse hearts indicated that CGS-21680 (100 nM) potentiated the effects of Iso on ϩdP/dt by ϳ60%. It is not clear why our findings are different from this study, but our observations are consistent with previous reports (19, 23) showing that A 2a AR stimulation did not potentiate ␤-adrenergic effects in rat isolated hearts and cardiomyocytes. Fig. 3 . Effects of the A2bAR agonist BAY 60-6583 on cardiac contractility (A) and coronary flow (B). Constant pressure-perfused and paced hearts were treated with increasing concentrations (100, 500, and 1,000 nM) of BAY 60-6583. Baseline contractility was measured before drug infusion, and all data are expressed as percent baseline values. Washout measurements were taken 10 min after responses to the 1,000 nM concentration were determined. Data are means Ϯ SE; n Ն 5 experiments/group. *P Ͻ 0.05 vs. baseline values. Our observations do indicate, however, that A 2a AR activation does modulate the A 1 AR antiadrenergic effect. Both WT and A 2a AR KO hearts displayed A 1 AR antiadrenergic responses, but this response was potentiated in A 2a AR KO hearts. At 2 nM Iso, A 1 AR antiadrenergic effects in A 2a AR KO hearts were increased by ϳ40% compared with WT hearts. With 10 nM Iso, only the blunting of ϩdP/dt was potentiated in A 2a AR KO hearts. These results suggest that the absence of A 2a AR increases the sensitivity of the A 1 AR antiadrenergic effect but may not alter the effects of higher levels of ␤-adrenergic receptor stimulation. These data are consistent with a previous observation showing that ZM-241385, an A 2a AR antagonist, potentiated the A 1 AR antiadrenergic response in isolated perfused rat hearts (19) . However, our present observations contradict those of Tikh et al. (30) , who reported that the A 1 AR antiadrenergic effect was significantly reduced in the A 2a AR KO mouse. Their conclusion was based on only a single concentration of Iso (10 nM), whereas we observed much greater modulation of the A 1 AR antiadrenergic effect at 2 versus 10 nM Iso. Although we used a slightly higher concentration of CCPA (200 vs. 100 nM) than those authors, we observed a similar A 1 AR antiadrenergic effect during 10 nM Iso stimulation. Our higher concentration of CCPA was associated with an ϳ20% increase in CF, indicating the activation of vascular A 2a AR, an effect that was absent in A 2a AR KO hearts.
Our observation that deletion of A 2a AR modulates cardiac A 1 AR is consistent with other reports suggesting that A 2a AR can modulate A 1 AR activity. It has been reported that A 1 AR and A 2a AR form functional heterodimers (in a heterologous expression system and native rat striatum and human brain caudate nucleus) in which A 2a AR has the ability to decrease the affinity of A 1 AR for agonists (3, 5) . There is also evidence that A 2a AR can modulate A 1 AR effects in the heart. We (15) reported that the AR antagonist ZM-241385, which exhibits some selectivity for A 2a AR, blocked the infarct size-reducing effects of CCPA in intact rats. It has also been reported that A 2a AR activation antagonizes the A 1 AR stimulatory effects of protein phosphatase 2A activity in the mouse myocardium, an effect that is absent in A 2a AR KO mice (29) . Thus, it is possible that, in the absence of A 2a AR, inhibitory effects on A 1 AR are relieved, and A 1 AR can exert a stronger antiadrenergic effect, as observed in this study.
A 2b AR modulation of cardiac contractility. A 2b AR is the least well-characterized AR in the heart, although its role in the modulation of CF is well recognized (22) . In contrast to A 1 AR and A 2a AR, A 2b AR displays a lower affinity for adenosine, and it has been reported that the expression of myocardial A 2b AR is much lower than that of A 1 AR and A 2a AR (20) . A 2b AR is coupled to a G s pathway and is also coupled to G q in select cell types, but A 2b AR G protein coupling in the heart has not been determined. In addition, there is a general lack of knowledge on the potential regulation of cardiac function via this receptor subtype.
Both the nonselective AR agonist NECA and the A 2b ARselective agonist BAY 60-6583 increased CF and contractility. Both agonists increased CF by ϳ50% at 100 nM, and this was associated with no effect on LV contractile function. Increasing the agonist concentrations resulted in little additional increases in CF but did significantly increase contractility (ϳ15-20%) assessed by all three parameters. In addition, after completion of the dose-response curves, the contractile effects of both agonists disappeared after a 10-min washout period, whereas CF remained elevated. These observations indicate that the contractile effects of both agonists were independent of the increases in CF. The increase in contractility with NECA was not apparent until a concentration of 1 M, consistent with the lower affinity of this agonist for A 2b AR. The effect of NECA on contractility was absent in A 2b AR KO hearts, although coronary vasodilation persisted due to its effects on A 2a AR (data not shown; n ϭ 2). The A 2b AR selectivity of BAY 60-6583 was confirmed by the lack of effect of this agonist on both CF and contractility in A 2b AR KO hearts. Despite the moderate increases in contractility with A 2b AR stimulation, ␤-adrenergic contractile responses were not altered by BAY 60-6583, and the A 1 AR antiadrenergic effect was not affected in the absence of A 2b AR.
Our observations that A 2b AR activation exerted a modest positive inotropic effect are consistent with a limited number of previous studies. It has been reported that adenosine and NECA (at high concentrations) produced small increases in contractility in isolated rat hearts, consistent with a possible A 2b AR effect (19) . Willems and Headrick (31) also reported a similar small, but sustained, flow-independent effect of aden- osine in isolated perfused mouse hearts and concluded that this was likely due to A 2b AR stimulation. In contrast, it has been shown that NECA increased contractility in isolated perfused mouse hearts by ϳ140% at a concentration of 100 nM in association with a 300% increase in CF (20) . However, it must be noted that these hearts were unpaced, and, given that NECA decreases HR via A 1 AR activation, interpretation of cardiac function with large changes in HR is very difficult. In a subsequent study by the same laboratory (28), BAY 60-6583 exerted a significant increase in LV pressure in isolated mouse hearts in parallel with increases in CF.
The indirect effects of A 2a AR and direct effects of A 2b AR on cardiac contractility are consistent with the expression of both AR subtypes in ventricular myocytes as assessed by real-time quantitative PCR. The pattern of AR subtype mRNA expression that we observed in mouse heart ventricular tissue is essentially identical to that reported previously (21) . However, A 2a AR and A 2b AR mRNA expression are significantly reduced in isolated ventricular myocytes, and even with our efforts to reduce contamination by preplating the myocyte suspension for 2 h, the presence of nonmyocytes cannot be completely excluded. Our observations that there was no change in A 1 AR expression in A 2a AR KO hearts and myocytes indicates that the potentiation of the A 1 AR antiadrenergic effect in these hearts is not likely to be due to an upregulation of A 1 AR. It has been published that KO of A 2b AR also does not alter the myocardial expression of other AR subtypes (10) .
Our observations that NECA and BAY 60-6583 exerted flow-independent increases in cardiac contractility are consistent with the expression of A 2b AR in cardiac myocytes, as supported by our RT-PCR data. A previous study (32) provided evidence for A 2b AR mRNA in isolated rat ventricular myocytes, but these authors did not describe procedures to reduce contamination by nonmyocytes. Furthermore, there is evidence for low-affinity A 2b AR in cultured fetal chick cardiomyocytes based on differential responses to several AR agonists (including NECA) and antagonists (17) . Although there is no direct evidence to date of A 2b AR protein expression in adult mammalian ventricular cardiomyocytes, the present functional data are consistent with this hypothesis. Given the increases in adenosine that occur during conditions of myocardial O 2 supply/demand imbalance, such as myocardial ischemia and hypoxia, it is possible that cardiac function may be modulated by low-affinity A 2b AR.
Conclusions. In summary, these findings indicate that A 2a AR and A 2b AR modulate cardiac contractility via indirect and direct effects, respectively. A 2a AR activation exerted no direct effects on cardiac contractility or the ␤-adrenergic contractile response. A 2b AR stimulation induced a modest increase in basal cardiac contractility independent of coronary vasodilation but had no effect on the ␤-adrenergic contractile response. Contractility experiments conducted using A 2a AR and A 2b AR KO mice further indicated that A 2a AR indirectly modulates cardiac contractility by attenuating the A 1 AR-mediated antiadrenergic response but that A 2b AR does not exhibit such indirect effects. These modulatory effects of A 2a AR and A 2b AR on ventricular contractility are consistent with our quantitative real-time PCR data, thus supporting the expression of these two AR subtypes on ventricular cardiomyocytes. Taken together, it appears that the two stimulatory ARs, A 2a AR and A 2b AR, play distinct roles in modulating cardiac contractility.
